Developer docs
API playgroundTry for free, no card

Search company profiles

Dermira

Full company profile

uuid00053ne

Namestring
Dermira
Websiteurl
dermira.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Dermira is a development-stage biotechnology company founded in 2010 and headquartered in Menlo Park, California. The company focused on developing and commercializing innovative new therapies in dermatology. Prior to its 2020 acquisition by Eli Lilly and Company, Dermira was publicly traded on NASDAQ under the ticker DERM and operated with 101-250 employees. Source data does not disclose Dermira's specific therapeutic candidates or pipeline composition, indicating the company's value was concentrated in clinical-stage dermatology assets that ultimately attracted a strategic acquirer.

Dermira financed its development-stage operations through repeated institutional capital raises rather than commercial product revenue. Between 2011 and 2019, the company executed approximately thirteen funding rounds aggregating roughly $1.1 billion, with notable investors including Bay City Capital, Canaan Partners, New Enterprise Associates, Maruho, Apple Tree Partners, Aisling Capital, Rock Springs Capital, Sabby Capital, Union Chimique Belge, and Athyrium Capital Management. The largest single rounds were a $278.1 million raise in May 2017 and a $193.8 million raise in March 2017, with a final $149.5 million round closed in March 2019 ahead of the Lilly transaction. No pricing models, product revenue, or commercial customer relationships are documented in source data.

Following Eli Lilly's acquisition, Dermira's dermatology assets were absorbed into Lilly's broader therapeutic portfolio, which spans oncology, autoimmune disease, dermatology, migraine, sleep apnea, diabetes, obesity, and Alzheimer's. Lilly distributes through healthcare provider networks and its LillyDirect direct-to-consumer pharmacy platform. The dermatology market Dermira addressed is sizeable and growing, with the global atopic dermatitis market projected at USD 7.13 billion in 2026 (7.75% CAGR) and the pruritus therapeutics market at USD 10.30 billion in 2025 (4.23% CAGR).

Short descriptiontext

Dermira was a development-stage dermatology biotech developing innovative therapies for skin conditions, headquartered in Menlo Park and acquired by Eli Lilly in 2020.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
dermatology therapeutics, biotech drug development, inflammatory skin treatments, atopic dermatitis therapies, prescription pharmaceuticals
Industry2 codes
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Dermatology Pharmaceuticals
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Dermira was a development-stage biopharmaceutical company that discovered, developed, and commercialized innovative new therapies for dermatologic conditions, with a primary focus on inflammatory skin diseases such as atopic dermatitis and chronic pruritus. Its offering centered on bringing prescription pharmaceutical treatments to market for high-prevalence, underserved dermatology patient populations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Atopic dermatitis market projected to grow from USD 7.13 billion (2026) to USD 12.97 billion by 2034 at 7.75% CAGR
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1TIRmed Pharma-Bachem
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic manufacturing partnership for production of dermatology therapeutics. Bachem provides peptide manufacturing capabilities while TIRmed Pharma contributes formulation expertise.

finance.yahoo.com
2KBI Biopharma-Infinimmune
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Manufacturing partnership for biopharmaceutical production. KBI Biopharma provides contract development and manufacturing services while Infinimmune contributes biologics development capabilities.

finance.yahoo.com
Strategic tierCoreTypeGTM or Marketing Partner
Description

Co-commercialization agreement for abrocitinib in India. Pfizer provides commercial infrastructure while Glenmark contributes local market access and distribution capabilities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty dermatology biotech developing and commercializing topical and oral therapies for inflammatory skin conditions including atopic dermatitis and seborrheic dermatitis. Closely comparable to Dermira as a focused dermatology innovator targeting the same patient populations with branded innovative therapies.

TypeBroad incumbent
Description

Global pharmaceutical company that co-commercializes abrocitinib (Cibinqo) for atopic dermatitis and is a Dermira partner. Comparable as both a potential competitor and a GTM partner in the atopic dermatitis JAK-inhibitor category.

TypeBroad incumbent
Description

Established biopharmaceutical company with Opzelura (ruxolitinib cream), a JAK inhibitor approved for atopic dermatitis and vitiligo. Directly competes in the same JAK-inhibitor dermatology space Dermira targeted, with broader commercial scale and an approved product already on market.

4Maruho
TypeRegional player
Description

Japan-based dermatology-specialty pharmaceutical company and early Dermira investor (led the 2013 Series 2 round). Comparable as a dermatology-focused pharma, with regional concentration in Japan rather than the U.S. and European markets Dermira primarily targeted.

TypeBroad incumbent
Description

Co-developer (with Regeneron) of Dupixent (dupilumab), the leading biologic for atopic dermatitis. Represents the dominant incumbent in Dermira's primary therapeutic area with a multi-billion-dollar biologic franchise.

6Bristol Myers Squibb
TypeBroad incumbent
Description

Global pharmaceutical company with Sotyktu (deucravacitinib) for psoriasis and a developing dermatology pipeline. Comparable as an incumbent in inflammatory skin disease therapeutics targeting the same dermatologist prescriber base.

TypeBroad incumbent
Description

Dermatology-focused specialty pharmaceutical company with a broad portfolio across therapeutic and aesthetic dermatology. Closely comparable business model to Dermira's dermatology-only focus, though at much larger commercial scale and with multiple approved products.

TypeDirect peer
Description

Clinical-stage biotechnology company developing inflammation and immunology therapeutics, including antibody-based treatments for dermatologic conditions. Comparable to Dermira as a development-stage biotech with dermatology-adjacent pipeline assets targeting inflammatory skin disease.

TypeBroad incumbent
Description

Global biopharmaceutical company with dermatology and immunology assets including bimekizumab. Comparable as a player in inflammatory skin disease therapeutics and notably connected to Dermira through executive Mark McDade (EVP at UCB).

TypeBroad incumbent
Description

Global pharmaceutical company marketing Rinvoq (upadacitinib) for atopic dermatitis and other inflammatory conditions. A direct competitor in the dermatology JAK-inhibitor and broader inflammatory skin disease market Dermira targeted.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dermira

Dermatology Pharmaceuticalsdermira.com

Dermira was a development-stage dermatology biotech developing innovative therapies for skin conditions, headquartered in Menlo Park and acquired by Eli Lilly in 2020.

What Dermira does

Dermira is a development-stage biotechnology company founded in 2010 and headquartered in Menlo Park, California. The company focused on developing and commercializing innovative new therapies in dermatology. Prior to its 2020 acquisition by Eli Lilly and Company, Dermira was publicly traded on NASDAQ under the ticker DERM and operated with 101-250 employees. Source data does not disclose Dermira's specific therapeutic candidates or pipeline composition, indicating the company's value was concentrated in clinical-stage dermatology assets that ultimately attracted a strategic acquirer.

Dermira financed its development-stage operations through repeated institutional capital raises rather than commercial product revenue. Between 2011 and 2019, the company executed approximately thirteen funding rounds aggregating roughly $1.1 billion, with notable investors including Bay City Capital, Canaan Partners, New Enterprise Associates, Maruho, Apple Tree Partners, Aisling Capital, Rock Springs Capital, Sabby Capital, Union Chimique Belge, and Athyrium Capital Management. The largest single rounds were a $278.1 million raise in May 2017 and a $193.8 million raise in March 2017, with a final $149.5 million round closed in March 2019 ahead of the Lilly transaction. No pricing models, product revenue, or commercial customer relationships are documented in source data.

Following Eli Lilly's acquisition, Dermira's dermatology assets were absorbed into Lilly's broader therapeutic portfolio, which spans oncology, autoimmune disease, dermatology, migraine, sleep apnea, diabetes, obesity, and Alzheimer's. Lilly distributes through healthcare provider networks and its LillyDirect direct-to-consumer pharmacy platform. The dermatology market Dermira addressed is sizeable and growing, with the global atopic dermatitis market projected at USD 7.13 billion in 2026 (7.75% CAGR) and the pruritus therapeutics market at USD 10.30 billion in 2025 (4.23% CAGR).

Dermira firmographics

Firmographics
Name
Dermira
Website
https://dermira.com
Company type
Private
Founded year
2010
Headcount range
11–50 employees
Short description
Dermira was a development-stage dermatology biotech developing innovative therapies for skin conditions, headquartered in Menlo Park and acquired by Eli Lilly in 2020.
Ownership category
akta.pro rank

Dermira industry classification

Industry
Product category
Dermatology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAK
Dermatology & Aesthetics Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals

Keywords

  • Dermatology therapeutics
  • Biotech drug development
  • Inflammatory skin treatments
  • Atopic dermatitis therapies
  • Prescription pharmaceuticals

Where Dermira is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Markets served

Dermira business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels3 records

Marketing channels4 records

Dermira product offering

Product offering

Core offering

Dermira was a development-stage biopharmaceutical company that discovered, developed, and commercialized innovative new therapies for dermatologic conditions, with a primary focus on inflammatory skin diseases such as atopic dermatitis and chronic pruritus. Its offering centered on bringing prescription pharmaceutical treatments to market for high-prevalence, underserved dermatology patient populations.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Atopic dermatitis market projected to grow from USD 7.13 billion (2026) to USD 12.97 billion by 2034 at 7.75% CAGR

Companies that use Dermira

Customer profile

Segments1 record

Ideal customer profiles1 record

Dermira technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Dermira partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • TIRmed Pharma-BachemcoreStrategic or Co-development PartnerStrategic manufacturing partnership for production of dermatology therapeutics. Bachem provides peptide manufacturing capabilities while TIRmed Pharma contributes formulation expertise.
  • KBI Biopharma-InfinimmunecoreStrategic or Co-development PartnerManufacturing partnership for biopharmaceutical production. KBI Biopharma provides contract development and manufacturing services while Infinimmune contributes biologics development capabilities.
  • Pfizer-Glenmark (for abrocitinib in India)coreGTM or Marketing PartnerCo-commercialization agreement for abrocitinib in India. Pfizer provides commercial infrastructure while Glenmark contributes local market access and distribution capabilities.

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Dermira competitors and assessment

Company assessment

Direct peers

  • Arcutis Biotherapeutics: Specialty dermatology biotech developing and commercializing topical and oral therapies for inflammatory skin conditions including atopic dermatitis and seborrheic dermatitis. Closely comparable to Dermira as a focused dermatology innovator targeting the same patient populations with branded innovative therapies.
  • AnaptysBio: Clinical-stage biotechnology company developing inflammation and immunology therapeutics, including antibody-based treatments for dermatologic conditions. Comparable to Dermira as a development-stage biotech with dermatology-adjacent pipeline assets targeting inflammatory skin disease.

Broad incumbents

  • Pfizer: Global pharmaceutical company that co-commercializes abrocitinib (Cibinqo) for atopic dermatitis and is a Dermira partner. Comparable as both a potential competitor and a GTM partner in the atopic dermatitis JAK-inhibitor category.
  • Incyte Corporation: Established biopharmaceutical company with Opzelura (ruxolitinib cream), a JAK inhibitor approved for atopic dermatitis and vitiligo. Directly competes in the same JAK-inhibitor dermatology space Dermira targeted, with broader commercial scale and an approved product already on market.
  • Sanofi: Co-developer (with Regeneron) of Dupixent (dupilumab), the leading biologic for atopic dermatitis. Represents the dominant incumbent in Dermira's primary therapeutic area with a multi-billion-dollar biologic franchise.
  • Bristol Myers Squibb: Global pharmaceutical company with Sotyktu (deucravacitinib) for psoriasis and a developing dermatology pipeline. Comparable as an incumbent in inflammatory skin disease therapeutics targeting the same dermatologist prescriber base.
  • Galderma: Dermatology-focused specialty pharmaceutical company with a broad portfolio across therapeutic and aesthetic dermatology. Closely comparable business model to Dermira's dermatology-only focus, though at much larger commercial scale and with multiple approved products.
  • UCB: Global biopharmaceutical company with dermatology and immunology assets including bimekizumab. Comparable as a player in inflammatory skin disease therapeutics and notably connected to Dermira through executive Mark McDade (EVP at UCB).
  • AbbVie: Global pharmaceutical company marketing Rinvoq (upadacitinib) for atopic dermatitis and other inflammatory conditions. A direct competitor in the dermatology JAK-inhibitor and broader inflammatory skin disease market Dermira targeted.

Regional players

  • Maruho: Japan-based dermatology-specialty pharmaceutical company and early Dermira investor (led the 2013 Series 2 round). Comparable as a dermatology-focused pharma, with regional concentration in Japan rather than the U.S. and European markets Dermira primarily targeted.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

Dermira social profiles

Digital presence

Dermira financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dermira leadership team

Management profile

Number of profiles

Profiles1 record

Dermira funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dermira M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dermira

What does Dermira do?

Dermira was a development-stage biopharmaceutical company that discovered, developed, and commercialized innovative new therapies for dermatologic conditions, with a primary focus on inflammatory skin diseases such as atopic dermatitis and chronic pruritus. Its offering centered on bringing prescription pharmaceutical treatments to market for high-prevalence, underserved dermatology patient populations.

When was Dermira founded?

Dermira was founded in 2010. It employs 11 to 50 people.

Where is Dermira based?

Dermira is headquartered in Menlo Park, United States, in the North America region.

Who are Dermira's main competitors?

Direct peers on record are Arcutis Biotherapeutics and AnaptysBio. Broad incumbents are Pfizer, Incyte Corporation, Sanofi, Bristol Myers Squibb, Galderma, UCB and AbbVie. Maruho is listed as a regional player.

Does Dermira have an API?

No public API is recorded for Dermira.

What industry is Dermira in?

Dermira's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals, with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewNektar Gets $90 Million Jury Award in Breach Suit Vs Eli LillyNektar Therapeutics won a $90 million jury verdict in its lawsuit against Eli Lilly over a 2017 licensing agreement for its autoimmune drug rezpeg. The jury found Eli Lilly breached the implied covenant of good faith and fair dealing, awarding damages plus interest. Nektar is still developing rezpeg and launched a phase 3 study in atopic dermatitis in July.VenturesquareABB partners with Sky Intelligence... Global strategy for physical AI data infrastructureSky Intelligence and ABB Robotics signed a cooperation framework to develop physical AI infrastructure for industrial and manufacturing sectors. The agreement combines ABB's RobotStudio simulation platform with Sky Intelligence's synthetic data generation technology. The companies plan to verify AI performance in ABB robot arm workstations and expand cooperation to product integration and joint market entry.스타트업엔(StartupN)Sky Intelligence has teamed up with ABB Robotics... launching a full-scale attack on the 'Physical AI' industrial manufacturing market.Sky Intelligence signed a cooperation framework agreement with ABB Robotics to jointly develop and verify Physical AI technology for industrial manufacturing. The partnership combines ABB's RobotStudio simulation platform with Sky Intelligence's synthetic data pipeline to test AI-driven robot operations. Future product integration and market entry are planned.GlobeNewswireJourney Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA®Journey Medical entered a definitive agreement to acquire QBREXZA from Dermira, a subsidiary of Eli Lilly, expected to close in Q2 2021. QBREXZA generated $24 million in U.S. net sales in 2020 and is the only FDA-approved topical for primary axillary hyperhidrosis. The acquisition expands Journey Medical's dermatology portfolio.PrwebDeimira Paa Baidoo: Content is the Only Everlasting Marketing TechniqueDeimira Paa Baidoo, CEO of Melcom Group, argues that content writing is the only lasting marketing technique, citing search engine algorithm changes and the permanence of on-site content. He says businesses investing in content perform better long-term, while paid ads are fixed-cost and fixed-timeframe.PR NewswireEvommune In-Licenses Three Development Programs Focused on Treating Inflammatory Conditions from Dermira, a Wholly-Owned Subsidiary of Eli Lilly and CompanyEvommune, Inc. entered into an exclusive license agreement with Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, to develop and commercialize three investigational programs for treating inflammatory diseases. The programs include IRAK4/TrkA (small molecule for innate inflammation), RORγt (small molecule for Th17 mediated inflammation), and MRGPRX2 (small molecule for chronic pruritus), with undisclosed upfront payment and potential milestone payments and royalties. Evommune's leadership team previously led the original development of these compounds at Dermira, positioning the company for pipeline expansion and long-term growth.NewswireDeimira Paa Baidoo: 'Solar Powered Homes Are an Economic Necessity'Deimira Paa Baidoo, a Calgary home builder, argues that solar panels are an economic necessity for property value. He cites rising grid energy costs and faster depreciation of homes without solar, and envisions future government mandates and remote work reducing mobility.PR NewswireLilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD)Eli Lilly and Company announced it will present 24 e-Posters from its dermatology portfolio at the virtual American Academy of Dermatology meeting, including data for Taltz, baricitinib, mirikizumab, and lebrikizumab. The data includes multi-year clinical trial results for treatments of psoriasis and atopic dermatitis. Lilly also highlighted its acquisition of Dermira as reinforcement of its commitment to expanding its dermatology pipeline.PR NewswireLilly Completes Acquisition of DermiraEli Lilly and Company completed its acquisition of Dermira, Inc. on February 20, 2020, through a tender offer and second-step merger. The $18.75-per-share cash deal attracted approximately 74.8% of Dermira's outstanding shares, with the transaction conducted under Delaware corporate law. The acquisition expands Lilly's dermatology portfolio with the addition of lebrikizumab, a Phase 3 investigational monoclonal antibody for atopic dermatitis, and the marketed treatment QBREXZA for excessive underarm sweating.PR NewswireLilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira AcquisitionEli Lilly reported strong fourth-quarter 2019 revenue of $6.114 billion, an 8% increase year-over-year, with full-year 2019 revenue reaching $22.319 billion, a 4% increase; EPS for Q4 grew to $1.64 reported or $1.73 non-GAAP. The company announced a definitive agreement to acquire Dermira, Inc. for approximately $1.1 billion in an all-cash transaction, expanding its immunology pipeline with lebrikizumab for atopic dermatitis. Lilly updated its 2020 EPS guidance to $6.18–$6.28 on a reported basis reflecting the pending Dermira acquisition, while reaffirming non-GAAP EPS guidance of $6.70–$6.80.